Concepedia

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial

R. Stahel, Urania Dafni, Oliver Gautschi, Enriqueta Felip, Alessandra Curioni‐Fontecedro, Solange Peters, Bartomeu Massutí, F. Cardenal, S. Ponce Aix, Martin Früh,

European Journal of Cancer · 2015 · 28 citations · 0 references

Concepts

MedicineOncologyPharmacologyMolecular OncologyPrecision OncologyThoracic OncologyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsTargeted Cancer TherapyTargeted TherapyEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingErlotinib TherapyMutationNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPhase Ii Investigation